Vor Biopharma Inc（VOR）资讯与事件VORVor Biopharma Inc

Vor Bio Announces New Analysis Results from Phase 3 Trial in China

Vor Bio (VOR) announced a new post hoc analysis from the Phase 3 trial conducted in China by its collaborator, RemeGen (REGMF), evaluating telitacicept in adults with generalized myasthenia gravis. The findings were presented in an oral presentation during the Myasthenia Gravis Foundation of America Scientific Session at the 2026 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting in Orlando, Florida. Key Findings from the Post Hoc 48-week Analysis: Among participants who reached MSE, 86.7% of MSE events were sustained at the next monthly assessment. More than half of participants with baseline MG-ADL scores of 6-8 and 9-10 achieved MSE during the 48-week study. MG-ADL responses continued to deepen from Week 24 through Week 48, with increasingly stringent response thresholds achieved over time and MG-ADL improvements of up to 13 points observed at Week 48. The probability of achieving MSE at any time over the 48-week study was approximately 42% among participants treated with telitacicept. Telitacicept was generally well tolerated through 48 weeks with no new safety signals observed, consistent with the previously reported safety profile from the study.

Vor Bio Files Automatic Mixed Securities Shelf

Vor Bio files automatic mixed securities shelf

Cash and Marketable Securities Reach $466.1 Million, Projected to Fund Operations into Early 2029

Cash, cash equivalents and marketable securities were $466.1 million as of June 30, 2026, which together with the $48.4 million net proceeds from at-the-market sales during July 2026, are projected to fund operations into early 2029.